Announcing a new article publication for BIO Integration journal. In this article the authors Xiao'en Shi, Xu Zhang, Xinlu Zhang, Haizhen Guo and Sheng Wang from Tianjin University, Tianjin, China discuss the integration of reactive oxygen species generation and prodrug activation for cancer therapy.
The combination of chemotherapeutic drugs and reactive oxygen species (ROS) can improve cancer treatment outcome. Many ROS-generation strategies can specifically consume tumor-inherent oxygen and generate ROS, resulting in amplified ROS level and aggravated hypoxia. Therefore, the ROS generation strategy can integrate with prodrug activation strategy to realize synergetic therapy.
In recent years, stimuli-responsive nanomedicines have been developed to realize the integration of ROS generation and prodrug activation. Triggered by a stimulus, nanomedicines can generate ROS at the tumor site, which can further activate the release of active drugs. The authors of this article summarize the latest progress of these nanomedicines and discuss the perspectives and challenges.
Article reference: Xiao'en Shi, Xu Zhang, Xinlu Zhang, Haizhen Guo and Sheng Wang, The Integration of Reactive Oxygen Species Generation and Prodrug Activation for Cancer Therapy. BIO Integration, 2021, https://doi.org/10.15212/bioi-2021-0011
BIO Integration is fully open access journal which will allow for the rapid dissemination of multidisciplinary views driving the progress of modern medicine.
As part of its mandate to help bring interesting work and knowledge from around the world to a wider audience, BIOI will actively support authors through open access publishing and through waiving author fees in its first years. Also, publication support for authors whose first language is not English will be offered in areas such as manuscript development, English language editing and artwork assistance.
###
BIOI is now open for submissions; articles can be submitted online at:
https://mc04.manuscriptcentral.com/bioi
Please visit http://www.bio-integration.org to learn more about the journal.
Editorial Board: https://bio-integration.org/editorial-board/
Please visit http://www.bio-integration.org to learn more about the journal.
Editorial Board: https://bio-integration.org/editorial-board/
BIOI is available on the IngentaConnect platform (https://www.ingentaconnect.com/content/cscript/bioi) and at the BIO Integration website (http://www.bio-integration.org).
Submissions may be made using ScholarOne (https://mc04.manuscriptcentral.com/bioi).
There are no author submission or article processing fees.
Follow BIOI on Twitter @JournalBio; Facebook (https://www.facebook.com/BIO-Integration-Journal-108140854107716/) and LinkedIn (https://www.linkedin.com/company/bio-integration-journal/).
ISSN 2712-0074
eISSN 2712-0082
Keywords: Cancer therapy, hypoxia, nanomedicine, prodrug, reactive oxygen species.
Journal
BIO Integration